Search Results - "Arnau, M A"

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria by Kaplan, A. P., Giménez‐Arnau, A. M., Saini, S. S.

“…The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria…”
Get full text

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria by Giménez-Arnau, A. M., Toubi, E., Marsland, A. M., Maurer, M.

“…This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is…”
Get full text

New‐onset and exacerbations of psoriasis after mRNA COVID‐19 vaccines: two sides of the same coin? by Pesqué, D., Lopez‐Trujillo, E., Marcantonio, O., Giménez‐Arnau, A.M., Pujol, R.M.

Get full text

Pityriasis rosea developing after COVID‐19 vaccination by Marcantonio‐Santa Cruz, O.Y., Vidal‐Navarro, A., Pesqué, D., Giménez‐Arnau, A.M., Pujol, R.M., Martin‐Ezquerra, G.

Get full text

Minimum standards on prevention, diagnosis and treatment of occupational and work‐related skin diseases in Europe – position paper of the COST Action StanDerm (TD 1206) by Alfonso, J.H., Bauer, A., Bensefa‐Colas, L., Boman, A., Bubas, M., Constandt, L., Crepy, M.N., Goncalo, M., Macan, J., Mahler, V., Mijakoski, D., Ramada Rodilla, J.M., Rustemeyer, T., Spring, P., John, S.M., Uter, W., Wilkinson, M., Giménez‐Arnau, A.M.

“…Background Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis,…”
Get full text

Contact allergy to preservatives: ESSCA results with the baseline series, 2009–2012 by Giménez‐Arnau, A.M., Deza, G., Bauer, A., Johnston, G.A., Mahler, V., Schuttelaar, M.‐L., Sanchez‐Perez, J., Silvestre, J.F., Wilkinson, M., Uter, W.

“…Background Allergic contact dermatitis caused by biocides is common and causes significant patient morbidity. Objective To describe the current frequency and…”
Get full text

Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices by Herman, A., Uter, W., Rustemeyer, T., Matura, M., Aalto‐Korte, K., Duus Johansen, J., Gonçalo, M., White, I.R., Balato, A., Giménez Arnau, A.M., Brockow, K., Mortz, C.G., Mahler, V., Goossens, A.

“…Background In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed…”
Get full text

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study by Soegiharto, R, Alizadeh Aghdam, M, Sørensen, J A, van Lindonk, E, Bulut Demir, F, Mohammad Porras, N, Matsuo, Y, Kiefer, L, Knulst, A C, Maurer, M, Ritchie, C, Rudenko, M, Kocatürk, E, Criado, R F J, Gregoriou, S, Bobylev, T, Kleinheinz, A, Takahagi, S, Hide, M, Giménez-Arnau, A M, Salman, A, Kara, R Oztas, Dikicier, B S, van Doorn, M B A, Thomsen, S F, van den Reek, J M P A, Röckmann, H

“…Long-term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking. To evaluate the…”
Get full text

Consensus on the Definition of Control and Remission in Chronic Urticaria by Giménez-Arnau, AM, Jáuregui, I, Silvestre-Salvador, JF, Valero, A, Ferrer, M, Sastre, J, Ortiz de Frutos, FJ, Labrador-Horrillo, M, Bartra, J, Miquel Miquel, J

“…The terms control and remission and other key terms used in chronic urticaria (CU) such as flare-up, relapse, exacerbation, and recurrence have not been fully…”
Get full text

Omalizumab for the treatment of chronic inducible urticaria in 80 patients by Exposito‐Serrano, V., Curto‐Barredo, L., Aguilera Peiro, P., Gómez Armayones, S., Serra‐Baldrich, E., Spertino, J., Bonfill Ortí, M., Figueras Nart, I., Melé‐Ninot, G., Baliu‐Piqué, C., Sala Cunill, A., Labrador‐Horrillo, M., Guilabert Vidal, A., Fernández Chico, N., Giménez‐Arnau, A.M.

Get full text

Chronic hand eczema in Europe: Patient experiences and perspectives (CHEPEP) in qualitative interviews by Rönsch, H., Schiffers, F., Ofenloch, R., Weisshaar, E., Buse, A. S., Hansen, A., John, S. M., Giménez Arnau, A. M., Pesqué, D., Agner, T., Nørreslet, L. B., Loman, L., Romeijn, G. L. E., Schuttellaar, M. L. A., Košćec Bjelajac, A., Macan, J., Apfelbacher, C., Bauer, A.

“…Background Chronic hand eczema (CHE) is a very common skin disease among the European population. It causes itch and pain and, in more severe cases, seriously…”
Get full text

What is urticaria? Expert opinion from the 1st Global Urticaria Forum by Maurer, M., Giménez-Arnau, A. M.

Get full text

Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria by Giménez Arnau, A M, Valero Santiago, A, Bartra Tomás, J, Jáuregui Presa, I, Labrador Horrillo, M, Miquel Miquel, F J, Ortiz de Frutos, J, Sastre, J, Silvestre Salvador, J F, Ferrer Puga, M

“…Chronic spontaneous urticaria (CSU) is a heterogeneous condition that can severely impact quality of life. Consequently, rapid disease control is essential…”
Get full text

Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab by Ogueta, I., Spertino, J., Deza, G., Alcantara Luna, S., Zaragoza Ninet, V., Pujol, R.M., Giménez‐Arnau, A.M.

Get full text

Standard and expanded series patch testing update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) by Navarro-Triviño, Francisco José, Borrego, Leopoldo, Silvestre-Salvador, Juan Francisco, Mercader-García, Pedro, Giménez-Arnau, Ana M, de Frutos, Francisco Javier Ortiz, Sanz-Sánchez, Tatiana, Melé-Ninot, Gemma, Sánchez-Gilo, Araceli, Zaragoza-Ninet, Violeta, Serra-Baldrich, Esther, Miquel-Miquel, Javier, Córdoba-Guijarro, Susana, Rodríguez-Serna, Mercedes, Ruíz-González, Inmaculada, Manuel Carrascosa-Carrillo, José, de la Fuente, Enrique Gómez, Pastor-Nieto, María Antonia, Heras-Mendaza, Felipe, González-Pérez, Ricardo, Guillén, Paloma Sánchez-Pedreño, Sánchez-Pérez, Javier, Gatica-Ortega, María Elena, Fernández-Redondo, Virginia, Hervella-Garcés, Marcos, Manrique-Martínez, Pilar, Guimaraens-Juanena, Dolores, García-Gavín, Juan, Giménez-Arnau, Elena, Figueras-Nart, Ignaci, Curto-Barredo, Laia, Carlos Armario-Hita, José

“…After the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish…”
Get full text

Omalizumab: living up to PROMises by Giménez‐Arnau, A.M.

“…Linked Article: Bérard et al. Br J Dermatol 2019; 180:56–66…”
Get full text

An individualized diagnostic approach based on guidelines for chronic urticaria (CU) by Giménez-Arnau, A.M., Grattan, C., Zuberbier, T., Toubi, E.

“…Chronic urticaria (CU), defined as the spontaneous or inducible appearance of hives, angioedema or both for 6 weeks or more, presents with a number of subtypes…”
Get full text

Epidemiological, clinical, and allergic profile of psoriatic patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC) by Verdaguer-Faja, J, Borrego, L, Mercader-García, P, González Pérez, R, Córdoba-Guijarro, S, Giménez-Arnau, A M, Ruiz-González, I, Miquel-Miquel, J, Francisco Silvestre, J, Ortiz de Frutos, F J, Tous-Romero, F, Sanz Sánchez, T, Rodríguez-Serna, M, Sánchez-Pérez, J, Serra Baldrich, E, Zaragoza-Ninet, V, Pastor-Nieto, M A, Gatica-Ortega, M E, Sánchez Gilo, A, Melé-Ninot, Gemma, Sánchez-Pedreño Guillén, P, Munera-Campos, M, Descalzo, M Á, García-Doval, I, Carrascosa, J M

“…Psoriasis is a chronic inflammatory dermatosis whose clinical and topographic distribution requires differential diagnosis, or the possible association with…”
Get full text

Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP) by Couselo-Rodríguez, C, Batalla, A, Carrascosa, J M, Chicharro, P, González-Quesada, A, de la Cueva, P, Giménez-Arnau, A M, Gilaberte, Y, Rodríguez-Serna, M, Montero-Vilchez, T, Ruiz-Villaverde, R, Elosua-González, M, Silvestre-Salvador, J F, Munera-Campos, M, Sánchez-Pérez, J, Carretero, G, Mauleón-Fernández, C, Curto-Barredo, L, Ballano-Ruiz, A, Botella-Estrada, R, Arias-Santiago, S, Navarro-Triviño, F J, Roustan-Gullón, G, Betlloch, I, Del Alcázar, E, Abalde-Pintos, M T, Suárez-Perez, J, García-Doval, I, Descalzo, M Á, Flórez, Á

“…The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this…”
Get full text

[Translated article] Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP) by Couselo-Rodríguez, C., Batalla, A., Carrascosa, J.M., Chicharro, P., González-Quesada, A., de la Cueva, P., Giménez-Arnau, A.M., Gilaberte, Y., Rodríguez-Serna, M., Montero-Vilchez, T., Ruiz-Villaverde, R., Elosua-González, M., Silvestre-Salvador, J.F., Munera-Campos, M., Sánchez-Pérez, J., Carretero, G., Mauleón-Fernández, C., Curto-Barredo, L., Ballano-Ruiz, A., Botella-Estrada, R., Arias-Santiago, S., Navarro-Triviño, F.J., Roustan-Gullón, G., Betlloch, I., del Alcázar, E., Abalde-Pintos, M.T., Suárez-Perez, J., García-Doval, I., Descalzo, M.Á., Flórez, Á.

“…The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this…”
Get full text